Additional Proxy Soliciting Materials (definitive) (defa14a)
19 Abril 2023 - 5:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
| | |
Filed by the Registrant ☒ | Filed by a Party other than the Registrant ☐ | |
Check the appropriate box:
☐Preliminary Proxy Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐Definitive Proxy Statement
☒Definitive Additional Materials
☐Soliciting Material under §240.14a-12
AEROVATE THERAPEUTICS, INC.
(Name of registrant as specified in its charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒No fee required.
☐Fee paid previously with preliminary materials.
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
| www.investorvote.com/AVTE
Step 1: Go to www.investorvote.com/AVTE.
Step 2: Click on the icon on the right to view meeting materials.
Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in.
Online
Go to www.investorvote.com/AVTE or scan the
QR code — login details are located in the
shaded bar below.
Stockholder Meeting Notice
03S1ND
+
+
Important Notice Regarding the Availability of Proxy Materials for the
Aerovate Therapeutics, Inc. Stockholder Meeting to be Held on June 6, 2023.
Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual
stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or
request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet.
We encourage you to access and review all of the important information contained in the proxy materials before voting. The
Proxy Statement and Annual Report on Form 10-K to stockholders are available at:
Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request
one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side
on or before Wednesday, May 24, 2023 to facilitate timely delivery.
2NOT
Easy Online Access — View your proxy materials and vote.
When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.
Votes submitted electronically must be received
by 11:59pm, (ET), on June 5, 2023
Step 4: Make your selections as instructed on each screen for your delivery preferences.
Step 5: Vote your shares.
Phone
Call toll free 1-800-652-VOTE (8683) within
the USA, US territories and Canada |
| Here’s how to order a copy of the proxy materials and select delivery preferences:
Current and future delivery requests can be submitted using the options below.
If you request an email copy, you will receive an email with a link to the current meeting materials.
PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.
— Internet – Go to www.investorvote.com/AVTE.
— Phone – Call us free of charge at 1-866-641-4276.
— Email – Send an email to investorvote@computershare.com with “Proxy Materials Aerovate Therapeutics, Inc.” in the subject line.
Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper
copy of the meeting materials.
To facilitate timely delivery, requests for a paper copy of proxy materials must be received by Wednesday, May 24, 2023.
Aerovate Therapeutics, Inc. Annual Meeting of Stockholders will be held on Tuesday, June 6, 2023 at the offices of RA Capital
Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116, at 9:00 a.m. Eastern Time.
Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.
The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposal 2:
1. Election of Directors:
01 - Allison Dorval
02 - Joshua Resnick, M.D.
2. Ratification of the appointment of KPMG LLP as Aerovate Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year
ending December 31, 2023.
PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to
receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.
Stockholder Meeting Notice |
Aerovate Therapeutics (NASDAQ:AVTE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aerovate Therapeutics (NASDAQ:AVTE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024